SELARL PHARMACIE NICE MERIDIA is a French company
founded 15 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in NICE (06200),
this company of category PME
shows in 2024 a revenue of 1.5 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - SELARL PHARMACIE NICE MERIDIA (SIREN 531646594)
Indicator
2024
2023
2022
2021
2020
2019
2018
2017
2016
Revenue
1 516 426 €
N/C
N/C
N/C
N/C
N/C
N/C
N/C
1 196 188 €
Net income
86 332 €
111 731 €
67 227 €
95 717 €
751 €
7 895 €
-45 667 €
14 218 €
3 069 €
EBITDA
89 609 €
N/C
N/C
N/C
N/C
N/C
N/C
N/C
74 564 €
Net margin
5.7%
N/C
N/C
N/C
N/C
N/C
N/C
N/C
0.3%
Revenue and income statement
In 2024, SELARL PHARMACIE NICE MERIDIA achieves revenue of 1.5 M€. Revenue is growing positively over 9 years (CAGR: +3.0%). After deducting consumption (915 k€), gross margin stands at 601 k€, i.e. a rate of 40%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 90 k€, representing 5.9% of revenue. The operating margin remains fragile, requiring cost vigilance. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 86 k€, i.e. 5.7% of revenue. This profit can be retained or distributed to shareholders.
Revenue (2024)
?
Revenue
Definition
Total amount of sales of goods and services made by the company.
Formula
Sales of goods + Sold production
1 516 426 €
Gross margin (2024)
?
Gross margin
Definition
Difference between revenue and cost of goods sold.
Formula
Revenue - Cost of goods consumed
601 022 €
EBITDA (2024)
?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity
89 609 €
EBIT (2024)
?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals
107 661 €
Net income (2024)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
86 332 €
EBITDA margin (2024)
?
EBITDA margin
Definition
Measures the company's operating profitability.
Formula
(EBE / CA) x 100
Interpretation
> 10% : Good profitability 5-10% : Average < 5% : Low
5.9%
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 145%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 33%. The balance between equity and debt is satisfactory.
Debt ratio (2024)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
144.602%
Financial autonomy (2024)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
32.919%
Cash flow / Revenue (2024)
?
Cash flow / Revenue
Definition
Self-financing capacity relative to revenue.
Formula
(CAF / CA) x 100
Interpretation
The higher the ratio, the more cash the company generates
-3.218%
Repayment capacity (2024)
?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent 3-5 years : Fair > 5 years : Warning
-11.156
Asset age ratio (2024)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
Debt ratio
1395.697
1139.193
3635.214
2531.498
2322.462
544.892
329.893
199.777
144.602
Financial autonomy
5.427
6.404
2.233
3.096
3.168
11.971
17.438
26.093
32.919
Repayment capacity
82.348
None
None
None
None
None
None
None
-11.156
Cash flow / Revenue
0.8%
None%
None%
None%
None%
None%
None%
None%
-3.218%
Sector positioning
Debt ratio
144.62024
2022
2023
2024
Q1: 16.46
Med: 58.48
Q3: 154.77
Average
In 2024, the debt ratio of SELARL PHARMACIE NICE MER... (144.60) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
Financial autonomy
32.92%2024
2022
2023
2024
Q1: 28.91%
Med: 49.95%
Q3: 69.47%
Average
In 2024, the financial autonomy of SELARL PHARMACIE NICE MER... (32.9%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
Repayment capacity
-11.16 years2024
2024
Q1: 0.52 years
Med: 3.19 years
Q3: 7.6 years
Excellent
In 2024, the repayment capacity of SELARL PHARMACIE NICE MER... (-11.16) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 170.45. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 7.1x. Operating income very largely covers interest expenses: high safety margin.
Liquidity ratio (2024)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
170.446
Interest coverage (2024)
?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
Liquidity ratio
151.067
160.187
163.336
129.368
121.6
135.002
137.851
163.319
170.446
Interest coverage
23.199
None
None
None
None
None
None
None
7.116
Sector positioning
Liquidity ratio
170.452024
2022
2023
2024
Q1: 129.46
Med: 182.14
Q3: 260.79
Average+21 pts over 3 years
In 2024, the liquidity ratio of SELARL PHARMACIE NICE MER... (170.45) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
Interest coverage
7.12x2024
2024
Q1: 0.0x
Med: 2.35x
Q3: 7.73x
Good
In 2024, the interest coverage of SELARL PHARMACIE NICE MER... (7.1x) ranks above the median of the sector. This ratio indicates how many times operating income covers interest expenses. This comfortable position offers an appreciable safety margin.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 3 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 53 days. Excellent situation: suppliers finance 50 days of the operating cycle (retail model). Inventory turnover is 49 days (= Average inventory / Cost of goods x 360). Overall, WCR represents 88 days of revenue, i.e. 372 k€ to permanently finance. Over 2016-2024, WCR increased by +77%, requiring additional financing.
Operating WCR (2024)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
371 524 €
Customer credit (2024)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
3 j
Supplier credit (2024)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
53 j
Inventory turnover (2024)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
49 j
WCR in days of revenue (2024)
?
WCR in days of revenue
Definition
Expresses working capital requirement in days of revenue.
Formula
(Operating WCR / Revenue) x 360
Interpretation
The fewer days, the better the working capital management
88 j
WCR and payment terms evolution SELARL PHARMACIE NICE MERIDIA
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
Operating WCR
210 326 €
0 €
0 €
0 €
0 €
0 €
0 €
0 €
371 524 €
Inventory turnover (days)
59
0
0
0
0
0
0
0
49
Customer payment term (days)
4
0
0
0
0
0
0
0
3
Supplier payment term (days)
57
0
0
0
0
0
0
0
53
Positioning of SELARL PHARMACIE NICE MERIDIA in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 225 transactions of similar company sales
in 2024,
the value of SELARL PHARMACIE NICE MERIDIA is estimated at
945 807 €
(range 682 820€ - 1 370 600€).
With an EBITDA of 89 609€, the sector multiple of 9.2x is applied.
The price/revenue ratio is 0.64x
(in line with sector norms).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2024
225 transactions
682k€945k€1370k€
945 807 €Range: 682 820€ - 1 370 600€
NAF 5 année 2024
Valuation detail by method
Ajustez les pondérations selon votre analyse
EBITDA Multiple50%
89 609 €×9.2x
Estimation827 491 €
542 043€ - 1 286 578€
Revenue Multiple30%
1 516 426 €×0.64x
Estimation970 033 €
813 114€ - 1 222 282€
Net Income Multiple20%
86 332 €×14.0x
Estimation1 205 259 €
839 323€ - 1 803 136€
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 225 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare SELARL PHARMACIE NICE MERIDIA with other companies in the same sector:
Frequently asked questions about SELARL PHARMACIE NICE MERIDIA
What is the revenue of SELARL PHARMACIE NICE MERIDIA ?
The revenue of SELARL PHARMACIE NICE MERIDIA in 2024 is 1.5 M€.
Is SELARL PHARMACIE NICE MERIDIA profitable?
Yes, SELARL PHARMACIE NICE MERIDIA generated a net profit of 86 k€ in 2024.
Where is the headquarters of SELARL PHARMACIE NICE MERIDIA ?
The headquarters of SELARL PHARMACIE NICE MERIDIA is located in NICE (06200), in the department Alpes-Maritimes.
Where to find the tax return of SELARL PHARMACIE NICE MERIDIA ?
The tax return of SELARL PHARMACIE NICE MERIDIA is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does SELARL PHARMACIE NICE MERIDIA operate?
SELARL PHARMACIE NICE MERIDIA operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart